F. Stephen Hodi, MD
Year elected: 2012
Current membership category: Active
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
United States of America
Dr. Hodi has pioneered advancements in the treatments for melanoma. He was the first to report the clinical use of CTLA-4 blocking antibodies in patients. The work included defining mechanisms of action of CTLA-4 blockade and led to the seminal study that revealed for the first time a survival advantage for patients and the basis for FDA approval. In addition, Dr. Hodi demonstrated the first successful use of a tyrosine-kinase inhibitor against KIT in melanoma, confirming the principle that melanoma may be treated based on the mutational status of patient’s tumor.
Harvard Medical School, Dana-Farber Cancer Institute (Primary)
William C. Hahn, MD, PhD is the representative at this institution.